Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signalin
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA).
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended December 31, 2024, and provided recent corporate updates.
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling t
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 25.55% | $947.95M | 0.75% |
XBI | 24.41% | $5.05B | 0.35% |
GNOM | 23.83% | $41.32M | 0.5% |
XPH | 22.11% | $139.13M | 0.35% |
PINK | 21.49% | $134.87M | 0.5% |
IBB | 21.34% | $5.37B | 0.45% |
EWM | 20.87% | $191.15M | 0.5% |
IWC | 20.54% | $765.89M | 0.6% |
ARKX | 20.38% | $280.88M | 0.75% |
SCYB | 20.33% | $1.06B | 0.03% |
PBE | 20.23% | $219.87M | 0.58% |
KRBN | 20.06% | $160.46M | 0.85% |
EPHE | 19.86% | $110.72M | 0.59% |
SRET | 19.60% | $180.60M | 0.59% |
HYLB | 19.48% | $3.68B | 0.05% |
BBHY | 19.39% | $408.23M | 0.07% |
BSJP | 18.88% | $952.96M | 0.43% |
SGOV | 18.77% | $46.49B | 0.09% |
SJNK | 18.74% | $4.35B | 0.4% |
PEY | 18.64% | $1.13B | 0.53% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CLRB | 51.34% | $11.09M | -92.84% | 0.00% |
PLAY | 34.28% | $768.60M | -59.30% | 0.00% |
ANAB | 32.18% | $571.45M | -24.02% | 0.00% |
VRA | 30.44% | $58.35M | -73.10% | 0.00% |
ARVN | 27.52% | $443.06M | -81.22% | 0.00% |
IBRX | 27.41% | $2.20B | -69.26% | 0.00% |
AGIO | 27.36% | $1.62B | -20.32% | 0.00% |
IMNM | 27.18% | $693.49M | -46.15% | 0.00% |
AUTL | 26.99% | $324.69M | -68.96% | 0.00% |
YMAB | 26.20% | $164.81M | -70.11% | 0.00% |
ARWR | 25.92% | $2.06B | -40.46% | 0.00% |
CARM | 25.90% | $8.06M | -86.22% | 0.00% |
VSTM | 25.40% | $367.12M | -45.66% | 0.00% |
GBIO | 24.96% | $25.66M | -89.90% | 0.00% |
CRSP | 24.96% | $3.07B | -37.50% | 0.00% |
RGNX | 24.44% | $417.84M | -48.68% | 0.00% |
CMBT | 24.22% | $1.83B | -53.46% | 11.61% |
ABCL | 24.14% | $611.89M | -44.59% | 0.00% |
GYRE | 23.92% | $973.99M | -33.53% | 0.00% |
NTLA | 23.67% | $816.23M | -69.95% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SHYM | -12.62% | $322.98M | 0.35% |
CTA | -12.41% | $1.03B | 0.76% |
TAIL | -11.05% | $145.16M | 0.59% |
BTC | -10.93% | $4.35B | 0.15% |
UNG | -10.57% | $371.70M | 1.06% |
UUP | -10.45% | $294.47M | 0.77% |
USDU | -9.30% | $174.58M | 0.5% |
IVOL | -8.77% | $351.97M | 1.02% |
FTSD | -8.25% | $212.45M | 0.25% |
VIXY | -7.87% | $102.66M | 0.85% |
UGA | -6.82% | $72.35M | 0.97% |
BTAL | -6.72% | $367.96M | 1.43% |
CANE | -6.39% | $10.43M | 0.29% |
KMLM | -6.06% | $188.70M | 0.9% |
DBE | -5.85% | $47.45M | 0.77% |
STPZ | -5.48% | $446.20M | 0.2% |
TDTT | -5.12% | $2.47B | 0.18% |
CMBS | -4.90% | $427.48M | 0.25% |
USO | -4.13% | $957.61M | 0.6% |
JUCY | -3.85% | $298.07M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTCO | <0.01% | $548.39M | 0.39% |
IEI | 0.03% | $16.09B | 0.15% |
IBMN | 0.05% | $446.08M | 0.18% |
TAXF | -0.05% | $500.52M | 0.29% |
DFIP | 0.05% | $875.08M | 0.11% |
GSG | -0.06% | $904.64M | 0.75% |
FCG | 0.07% | $338.25M | 0.6% |
GDX | -0.08% | $14.15B | 0.51% |
TLTW | -0.08% | $1.03B | 0.35% |
FLMI | -0.09% | $645.61M | 0.3% |
HODL | -0.09% | $1.50B | 0.25% |
BITB | 0.10% | $3.89B | 0.2% |
THTA | -0.11% | $35.75M | 0.49% |
PALL | -0.11% | $340.99M | 0.6% |
VGIT | -0.12% | $31.35B | 0.04% |
ARKB | 0.14% | $4.92B | 0.21% |
GTIP | 0.16% | $144.94M | 0.12% |
SCHP | -0.19% | $12.78B | 0.03% |
EZBC | 0.20% | $518.88M | 0.29% |
BRRR | 0.21% | $620.36M | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LQDT | -16.74% | $788.63M | +28.75% | 0.00% |
SFIX | -15.42% | $570.57M | +79.35% | 0.00% |
CRK | -13.60% | $6.98B | +124.08% | 0.00% |
XGN | -11.38% | $127.20M | +204.71% | 0.00% |
RLX | -11.08% | $1.76B | -6.28% | 0.52% |
REVG | -8.88% | $1.96B | +45.54% | 0.58% |
EQT | -8.79% | $33.74B | +37.70% | 1.13% |
RRC | -8.70% | $9.66B | +9.93% | 0.83% |
AR | -8.67% | $12.58B | +18.01% | 0.00% |
GFI | -7.46% | $17.93B | +18.45% | 2.72% |
GIFI | -7.38% | $99.94M | -9.14% | 0.00% |
FIGS | -7.24% | $750.99M | -22.09% | 0.00% |
GME | -6.70% | $12.85B | -27.36% | 0.00% |
FMTO | -6.60% | $42.73M | -99.94% | 0.00% |
TW | -6.59% | $29.87B | +24.28% | 0.30% |
CTRA | -6.22% | $19.07B | -10.18% | 3.48% |
NG | -6.14% | $1.17B | +11.11% | 0.00% |
PAY | -5.89% | $4.79B | +100.47% | 0.00% |
PLYA | -5.88% | $1.65B | +57.56% | 0.00% |
BVN | -5.85% | $3.61B | -17.76% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KNSL | -0.01% | $10.23B | +14.74% | 0.14% |
CASY | -0.01% | $15.99B | +27.59% | 0.46% |
ENIC | -0.02% | $5.49B | +23.29% | 0.00% |
CLMT | -0.02% | $1.20B | -9.76% | 0.00% |
WDS | 0.03% | $27.09B | -23.34% | 8.60% |
AVGO | -0.03% | $1.09T | +61.62% | 3.04% |
CBOE | -0.04% | $22.36B | +20.11% | 1.14% |
ECG | 0.04% | $3.08B | +23.06% | 0.00% |
CIO | -0.05% | $197.35M | -5.05% | 8.11% |
SPT | -0.06% | $1.41B | -17.88% | 0.00% |
PAGP | -0.07% | $3.68B | +1.91% | 0.00% |
CME | 0.08% | $95.96B | +27.86% | 3.91% |
CIEN | 0.09% | $11.30B | +61.25% | 0.00% |
GOOGL | -0.10% | $2.01T | -4.14% | 0.48% |
ZCMD | 0.10% | $29.04M | -16.67% | 0.00% |
OXBR | 0.12% | $14.96M | +27.20% | 0.00% |
SOHU | -0.13% | $329.22M | -8.06% | 0.00% |
EQNR | -0.14% | $63.90B | -13.15% | 5.98% |
FSM | 0.16% | $1.66B | +0.93% | 0.00% |
GOOG | -0.18% | $2.02T | -4.07% | 0.48% |
Current Value
$1.651 Year Return
Current Value
$1.651 Year Return